There is provided a compound represented by the following formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof. [In the formula (I), A is a 8- to 10-membered partially saturated or aromatic fused bicyclic nitrogen-containing heterocyclic group having 1 to 3 nitrogen atoms, R1 is a hydroxy group, a halogen atom, a cyano group or the like, n is any integer of 0 to 3, B is a 3- to 7-membered monocyclic saturated or partially saturated cyclic hydrocarbon group and may contain 1 or 2 oxygen atoms, sulfur atoms, nitrogen atoms or the like as ring constituents, R2 is a substituent present on a carbon atom or nitrogen atom forming B, m is any integer of 0 to 3, Q is a bond or a C1-4 alkylene group, R3 and R4 are the same or different and are each a hydrogen atom, a halogen atom, a C1-4 alkyl group or the like, and R5 and R6 are the same or different and are each a hydrogen atom, a halogen atom, a C1-4 alkyl group or the like.]
